IMARC Research’s whitepaper investigates the differences between the drug and medical device clinical research process. First and foremost, there is a common thread that ties the seemingly different clinical research processes together…patients. Real people exist on the other side of an investigational product and they face risk when they choose to take part in a clinical research study. So while the investigations of drugs and devices have their differences, by design these differences are intended to accomplish the game goal: to safeguard those research participants while bringing safe and effective products to the market as quickly as possible.
The whitepaper was written by Sandra Maddock, CEO and President of IMARC. She investigates how the process of getting a drug to the finish line may look a little different than getting a device to the finish line. Either way, the road to that finish line requires an ethical commitment combined with the proper controls and an understanding the differences – in the details – between drugs and devices.
Understanding these similarities and appreciating the differences is important for clinical researchers who are involved in both drug and device trials.Feel free to download the white paper and let us know what you think.